1-3 of 3
Thomas Mathew
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Thomas Mathew, Koji Sasaki, Yesid Alvarado Valero, Danielle Hammond, Fadi G. Haddad, William G. Wierda, Alessandra Ferrajoli
Journal: Blood
Blood (2024) 144 (Supplement 1): 4631.
https://doi.org/10.1182/blood-2024-198701
Published: 2024
Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 6524.
https://doi.org/10.1182/blood-2023-178774
Published: 2023
Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Jan A. Burger, Mariela Sivina, Nitin Jain, Ekaterina Kim, Tapan Kadia, Zeev Estrov, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Jeffrey Jorgensen, Jianling Li, Mei Cheng, Fong Clow, Maro Ohanian, Michael Andreeff, Thomas Mathew, Philip Thompson, Hagop Kantarjian, Susan O’Brien, William G. Wierda, Alessandra Ferrajoli, Michael J. Keating
Journal: Blood
Blood (2019) 133 (10): 1011–1019.
https://doi.org/10.1182/blood-2018-10-879429
Published: 2019
Includes: Supplemental data